BCAT1 Enzyme

BCAT1

To block its activity, the researchers used a compound called ERG240, which has been developed by the US-based company Ergon Pharmaceuticals.  The compound, which mimics the amino acid leucine, binds the enzyme, preventing it from altering the normal activity of the Krebs cycle.  Read More

2017-08-17T18:21:04+00:00